CTR20262765 YP004 Wet age-related macular degeneration Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20262765 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 3 August 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20262765 is a hot trial to watch
Wet age-related macular degeneration is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20262765 is notable because it evaluates YP004 in a Phase 1 design sponsored by Chengdu Yuanpu Biotechnology Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20262765 |
| Official title | 评估单次和多次玻璃体腔注射 YP004 在新生血管性年龄相关性黄斑变性试验参与者中的安全性、耐受性、药代动力学特征和初步有效性的开放、多中心、剂量递增的Ⅰ期临床研究 |
| Phase / status | Phase 1 / 进行中 （尚未招募） |
| Intervention | YP004 |
| Sponsor | Chengdu Yuanpu Biotechnology Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | SAD，0-29天 MAD，0-113天 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 1 study of YP004 in Wet age-related macular degeneration.
Allocation is 非随机化, masking is 开放, and the intervention model is 单臂试验. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (SAD，0-29天 MAD，0-113天) — 眼部及全身所有不良事件（AE）、治疗期不良事件（TEAE）和严重不良事件（SAE）的发生例数、发生率、严重程度、与试验药物或治疗的相关程度等；
- Primary endpoint (SAD，0-29天 MAD，0-113天) — 各剂量组生命体征、体格检查、实验室检查、心电图、眼科检查等检查结果的变化；DLT观察期间各剂量组中DLT的发生例数和发生率。
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: YP004 is indexed as Fusion protein, with target VEGF, mechanism VEGF inhibitors, and global highest development status Phase 1.
Company & Deal Intelligence MCP profile: Chengdu Yuanpu Biotechnology Co., Ltd. is resolved to a normalized organization record in Wuhan, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20262765 provides a focused lens on Wet age-related macular degeneration development. Its value will be determined by whether YP004 can convert the current Phase 1 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
